Skip to content

Released May 13, 2024, after the close

10-Q filed May 13, 2024, 43 days after period end · 0000950170-24-058718

Q1 2024 · 10-Q
Revenue$13.01M+2.6% vs Q1 2023−88.6% vs Q4 2023
Net Income-$58.21MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.59N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$56,591,000N/M
Operating Cash Flow-$64,741,000N/M
Margins · derived
Operating margin-435.0%−101.8 pt vs Q1 2023
Net margin-447.5%−52.6 pt vs Q1 2023

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$13.01M$12.67M$5.90M$14.66M
Net Income-$58.21M-$50.05M-$39.11M-$30.36M
EPS Diluted-$0.59-$0.85-$0.84-$0.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR